Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference
31 Julho 2023 - 10:00AM
Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ:
GRCL), a global clinical-stage biopharmaceutical company dedicated
to developing innovative and highly efficacious cell therapies for
the treatment of cancer and autoimmune diseases, today announced
that the management team will participate in the BTIG Virtual
Biotechnology Conference on August 7 - 8.
The Gracell team is scheduled to present on August 8th at 11:00
am ET and will host investor meetings at the conference on August
7-8.
About Gracell Gracell Biotechnologies
Inc. ("Gracell") is a global clinical-stage biopharmaceutical
company dedicated to discovering and developing breakthrough cell
and gene therapies. Leveraging its pioneering FasTCAR and TruUCAR
technology platforms and SMART CARTTM technology
module, Gracell is developing a rich clinical-stage pipeline
of multiple autologous and allogeneic product candidates with the
potential to overcome major industry challenges that persist with
conventional CAR-T therapies, including lengthy manufacturing time,
suboptimal cell quality, high therapy cost and lack of effective
CAR-T therapies for solid tumors. For more information on Gracell,
please visit www.gracellbio.com. Follow @GracellBio on
LinkedIn.
Media contacts
Marvin Tang
marvin.tang@gracellbio.com
Jessica Laub
jessica.laub@westwicke.com
Investor contacts
Gracie Tong
gracie.tong@gracellbio.com
Stephanie Carrington
stephanie.carrington@westwicke.com
Gracell Biotechnologies (NASDAQ:GRCL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Gracell Biotechnologies (NASDAQ:GRCL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024